

Literatur:

1. AOK-Bundesverband & Deutschem Krebsforschungszentrum (DKFZ) Public Health Index 2025 - Gesundheitsschutz im europäischen Vergleich. <https://www.aok.de/pp/public-health/index/#c62861>. 2025
2. Jasilionis D, van Raalte AA, Klusener S, Grigoriev P. The underwhelming German life expectancy. Eur J Epidemiol. 2023;38:839-850
3. Baldus S, Lauterbach K. Prevention-centered health care in Germany - a nation in need to turn the tide. Eur J Epidemiol. 2023;38:835-837
4. Weintraub WS, Boden WE. Achieving successful prevention of coronary artery disease: a worldwide call to action. European Heart Journal. 2024;45:4197-4199
5. DESTATIS - Statistisches Bundesamt - Todesursachen. <https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Todesursachen/inhalt.html?templateQueryString=todesursachen>. 2026
6. Münzel T, Crea F, Rajagopalan S, Lüscher T. Nicotine and the cardiovascular system: unmasking a global public health threat. European Heart Journal. 2025
7. Monteiro CA, Louzada MLC, Steele-Martinez E, Cannon G, Andrade GC, Baker P, Bes-Rastrollo M, Bonaccio M, Gearhardt AN, Khandpur N, Kolby M, Levy RB, Machado PP, Moubarac J-C, Rezende LFM, Rivera JA, Scrinis G, Srouf B, Swinburn B, Touvier M. Ultra-processed foods and human health: the main thesis and the evidence. The Lancet. 2025;406:2667-2684
8. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Boren J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgozoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459-2472
9. Siri-Tarino PW, Krauss RM. The early years of lipoprotein research: from discovery to clinical application. Journal of lipid research. 2016;57:1771-1777
10. Arzneimittel-Richtlinie Anlage III. https://www.g-ba.de/downloads/40-268-851/2008-12-18-AMR-Neufassung_TrGr.pdf. 2008
11. Arzneimittel-Richtlinie Anlage III. https://www.g-ba.de/downloads/83-691-1036/AM-RL-III-Verordnungseinschraenkungen_2025-10-09.pdf. 2025

12. Silber S, Jarre F, Pittrow D, Klotsche J, Pieper L, Zeiher AM, Wittchen HU, Studiengruppe D. Kardiovaskuläre Risikoabschätzung in der Hausarztpraxis (DETECT) Wie gut stimmt die Hausarzteinschätzung mit den etablierten Risikoscores überein? Medizinische Klinik. 2008;103:638-645
13. Grammer TB, Dressel A, Gergei I, Kleber ME, Laufs U, Scharnagl H, Nixdorff U, Klotsche J, Pieper L, Pittrow D, Silber S, Wittchen HU, März W. Cardiovascular risk algorithms in primary care: Results from the DETECT study. Sci Rep. 2019;9:1101
14. Mueller AS, Leipsic J, Tomey M, Argulian E, Narula J, Ahmadi A. Limitations of Risk- and Symptom-Based Screening in Predicting First Myocardial Infarction. JACC Adv. 2025;4:102361
15. Der arriba Score. <https://arriba-hausarzt.de>.
16. DEGAM S3-Leitlinie: Hausärztliche Risikoberatung zur kardiovaskulären Prävention, Langfassung und Kurzfassung. <https://www.degam.de/leitlinie-s3-053-024>. 2024
17. Der PROCAM Gesundheitstest. <https://www.assmann-stiftung.de/procam-tests/>.
18. ESC-HEART SCORE (SCORE2 and SCORE2-OP). https://heartscore.escardio.org/Calculate/quickcalculator.aspx?model=moderate&gl=1*1hibpj8*_gcl_au*MTg0MjQwMDA1My4xNzE5MTQzNTkx*_ga*MTczMzgXNzQ5MS4xNjQ4MjA0MDk1*_ga_5Y189L6T14*MTcxOTc0NjQxNi42MS4xLjE3MTk3NDY0NjMuMTMuMC4w*_ga_TEGGEERRV6*MTcxOTc0NjQzMy4zLjEuMTcxOTc0NjQ2My4wLjAuMA..
19. Silber S, Schneider T, Mehilli J, Rolf A. Bewertung der nichtinvasiven CT-Koronarangiographie (CCTA) als neue Leistung der gesetzlichen Krankenversicherungen: Für welche Patienten ist sie zugelassen ? Für welche nicht ? Was ist zu beachten? – DGK-Stellungnahme <https://link.springer.com/article/10.1007/s12181-025-00786-0>. Die Kardiologie. 2026;20:190 - 203
20. Silber S, Parhofer KG. Unterscheidung von Primär- versus Sekundärprävention noch zeitgemäß? MMW Fortschr Med. 2026;168:48-51
21. Silber S. Kennen Sie Ihr Herzinfarktrisiko? MMW Fortschr Med. 2018;160:38-44
22. Grandhi GR, Mirbolouk M, Dardari ZA, Al-Mallah MH, Rumberger JA, Shaw LJ, Blankstein R, Miedema MD, Berman DS, Budoff MJ, Krumholz HM, Blaha MJ, Nasir K. Interplay of Coronary Artery Calcium and Risk Factors for Predicting CVD/CHD Mortality: The CAC Consortium. JACC Cardiovasc Imaging. 2020;13:1175-1186
23. Budoff MJ, Kinnering A, Gransar H, Achenbach S, Al-Mallah M, Bax JJ, Berman DS, Cademartiri F, Callister TQ, Chang HJ, Chow BJW, Cury RC, Feuchtner G, Hadamitzky M, Hausleiter J, Kaufmann PA, Leipsic J, Lin FY, Kim YJ, Marques H, Pontone G,

- Rubinshtein R, Shaw LJ, Villines TC, Min JK, Investigators C. When Does a Calcium Score Equate to Secondary Prevention?: Insights From the Multinational CONFIRM Registry. *JACC Cardiovasc Imaging*. 2023;16:1181-1189
24. Cainzos-Achirica M, Miedema MD, McEvoy JW, Al Rifai M, Greenland P, Dardari Z, Budoff M, Blumenthal RS, Yeboah J, Duprez DA, Mortensen MB, Dzaye O, Hong J, Nasir K, Blaha MJ. Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis). *Circulation*. 2020;141:1541-1553
 25. Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, Delgado V, Fabin N, Ference BA, Graham IM, Landmesser U, Laufs U, Mihaylova B, Nordestgaard BG, Richter DJ, Sabatine MS, Group EESD. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *European Heart Journal*. 2025;46:4359-4378
 26. Ferrante G, Catapano F, Bacallao B, Romano I, Di Stefano V, Celata A, Battaglia V, Carli S, Del Monaco G, Gioia F, F. Amata F, Latini A, D'andrea M, Francone MC, G. The role of coronary artery calcium score and european score2 in primary prevention of cardiovascular disease. *Europ Heart J*, 45 (Suppl1). 2024
 27. Temtem M, Mendonca MI, Gomes Serrao M, Santos M, Sa D, Sousa F, Soares C, Rodrigues R, Henriques E, Freitas S, Borges S, Rodrigues M, Guerra G, Drumond Freitas A, Sousa AC, Palma Dos Reis R. Predictive improvement of adding coronary calcium score and a genetic risk score to a traditional risk model for cardiovascular event prediction. *European journal of preventive cardiology*. 2024;31:709-715
 28. Mitchell JD, Fergestrom N, Gage BF, Paisley R, Moon P, Novak E, Cheezum M, Shaw LJ, Villines TC. Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring. *J Am Coll Cardiol*. 2018;72:3233-3242
 29. Silber S. Wirklich gesund? So bestimmt man das persönliche kardiovaskuläre Risiko. *MMW Fortschr Med*. . 2022;164:32-36
 30. Wang X, Le EPV, Rajani NK, Hudson-Peacock NJ, Pavey H, Tarkin JM, Babar J, Williams MC, Gopalan D, Rudd JHF. A zero coronary artery calcium score in patients with stable chest pain is associated with a good prognosis, despite risk of non-calcified plaques. *Open Heart*. 2019;6:e000945
 31. Peng AW, Dardari ZA, Blumenthal RS, Dzaye O, Obisesan OH, Iftekhhar Uddin SM, Nasir K, Blankstein R, Budoff MJ, Bodtker Mortensen M, Joshi PH, Page J, Blaha MJ. Very High Coronary Artery Calcium (≥ 1000) and Association With Cardiovascular Disease Events, Non-Cardiovascular Disease Outcomes, and Mortality: Results From MESA. *Circulation*. 2021;143:1571-1583

32. Silber S, Keller M. Verdacht auf KHK: Wie heute in der hausärztlichen Praxis vorgehen? MMW Fortschr. Med. 2025;167:38-42
33. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S, Group ESCSD. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315-2381
34. Eckstein HH, et. al. S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der extracraniellen Carotisstenose. <https://register.awmf.org/de/leitlinien/detail/004-028>. 2020
35. Naylor AR, Ricco JB, de Borst GJ, Debus S, de Haro J, Halliday A, Hamilton G, Kakkis J, Kakkos S, Lepidi S, Markus HS, McCabe DJ, Roy J, Sillesen H, van den Berg JC, Vermassen F, Esvs Guidelines C, Kolh P, Chakfe N, Hinchliffe RJ, Koncar I, Lindholt JS, Vega de Ceniga M, Verzini F, Esvs Guideline R, Archie J, Bellmunt S, Chaudhuri A, Koelemay M, Lindahl AK, Padberg F, Venermo M. Editor's Choice - Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. 2018;55:3-81
36. Lee J, Kang MW, Oh J-i, Kim M, Koh JH, Kang E, Cho JM, Cho S, Kim SG, Lee S, Kim Y, Jung S, Huh H, Kim DK, Han K, Park S. Association between delayed statin initiation after high LDL-cholesterol detection and cardiovascular risk in general health screening examinees. European Heart Journal - Quality of Care and Clinical Outcomes. 2025;11:1377-1387
37. Bundesärztekammer. Medikamentöse Cholesterinsenkung zur Vorbeugung kardiovaskulärer Ereignisse Version 2.0. https://www.akdae.de/fileadmin/user_upload/akdae/Arzneimitteltherapie/LF/PDF/Cholesterinsenkung.pdf. 2023
38. Nationale Versorgungsleitlinie (NVL) - Chronische KHK, Version 7.0. <https://register.awmf.org/de/leitlinien/detail/nvl-004>. 2024
39. Mehilli J, Eckardt L, Laufs U, Boer J, Birkemeyer R, Frantz S, Volker Schächinger V, Mahfoud F, Perings C, Ghanem A, Linke A, Westermann D, Ertl G, Nowak B, Henke N, Langheim E, Thiele H. Stellungnahme zur kritischen Bewertung der Nationalen VersorgungsLeitlinie zur chronischen koronaren Herzerkrankung. Aus der Kommission für Klinische Kardiovaskuläre Medizin der DGK in Kooperation mit der DGIM und der DGPR. 2025;19:218-224

40. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, Societies ESCNC, Group ESCSD. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. 2021;42:3227-3337
41. Preiss D, Tobert JA, Hovingh GK, Reith C. Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar. *J Am Coll Cardiol*. 2020;75:1945-1955
42. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. *Jama*. 2016;316:1289-1297
43. Parhofer KG, Aguiar C, Banach M, Drexel H, Gouni-Berthold I, Pérez de Isla L, Rietzschel E, Zambon A, Ray KK. Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment. *Eur Heart J Cardiovasc Pharmacother*. 2025;11:367-379
44. Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferrières J, Laufs U, Mostaza JM, Nanchen D, Rietzschel E, Strandberg T, Toplak H, Visseren FLJ, Catapano AL. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. *The Lancet Regional Health – Europe*. 2023;29
45. Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, Murphy J, Banach M, De Servi S, Gaita D, Gouni-Berthold I, Hovingh GK, Jozwiak JJ, Jukema JW, Kiss RG, Kownator S, Iversen HK, Maher V, Masana L, Parkhomenko A, Peeters A, Clifford P, Raslova K, Siostrzonek P, Romeo S, Tousoulis D, Vlachopoulos C, Vrablik M, Catapano AL, Poulter NR. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. *European journal of preventive cardiology*. 2021;28:1279-1289
46. Stürzebecher PE, Tünnemann-Tarr A, Tuppatsch K, Laufs U. Behandlung und LDL-Cholesterin-Einstellung von Patienten mit hohem und sehr hohem kardiovaskulärem Risiko in Deutschland und im europäischen Vergleich – Daten des SANTORINI-Registers. *Dtsch Med Wochenschr*. 2023;148:55-64
47. Schubert J, Leosdottir M, Lindahl B, Westerbergh J, Melhus H, Modica A, Cater N, Brinck J, Ray KK, Hagström E. Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry. *Eur Heart J*. 2024;45:4204-4215

48. McEvoy JW, Jennings C, Kotseva K, De Bacquer D, De Backer G, Erlund I, Vihervaara T, Lip GYH, Ray KK, Rydén L, Abreu A, Almahmeed W, Ambari AM, Ge J, Hasan-Ali H, Huo Y, Jankowski P, Jimenez RM, Li Y, Mahmood Zuhdi AS, Makubi A, Mbakwem AC, Mbau L, Navarro Estrada JL, Ogah OS, Ogola EN, Quintero–Baiz A, Sani MU, Sosa Liprandi MI, Tan JWC, Urina Triana MA, Yeo TJ, Ganly S, Adamska A, Wood D, Investigators obotl. Variation in secondary prevention of coronary heart disease: the INTERASPIRE study. *European Heart Journal*. 2024;45:4184-4196
49. Koenig W, Lorenz ES, Beier L, Gouni-Berthold I. Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany. *Clin Res Cardiol*. 2024;113:812-821
50. Haertel F, Makhmudova U, Geiling JA, Lauer B, Möbius-Winkler S, Otto S, Schulze PC, Weingärtner O. Less intensive lipid-lowering therapy after ST-elevation myocardial infarction is associated with cardiovascular events: 2-year follow-up of "Jena auf Ziel". *Clin Res Cardiol*. 2025
51. Kurpas D, Petrazzuoli F, Shantsila E, Antonopoulou M, Christodorescu R, Korzh O, Kumler T, Kyriakou M, Neubeck L, Papakonstantinou PE, Richter D, Semb AG, Vargas MF, Ferrini M. Implementation of prevention guidelines in primary healthcare: a scientific statement of the European Association of Preventive Cardiology of the ESC, the ESC Council for Cardiology Practice, the Association of Cardiovascular Nursing & Allied Professions of the ESC, WONCA Europe, and EURIPA. *European journal of preventive cardiology*. 2025
52. Wilkinson C, Nadarajah R, Prescott EIB, Thomson B, Vedanthan R, Ribeiro ALP, Gale CP. Socioeconomic deprivation: barriers to guideline implementation for cardiovascular disease. *European Heart Journal*. 2025;47:292-305
53. Stein EA, Raal FJ. Targeting LDL: Is lower better and is it safe? *Best Practice & Research Clinical Endocrinology & Metabolism*. 2014;28:309-324

Autor:

Prof. Dr. med. Sigmund Silber
Kardiologie Zentrum München
Tal 21
80331 München
sigmund@silber.com

Interessenkonflikte:

keine